Company Profile
Alizyme is a speciality biopharmaceutical development company, based in Cambridge, UK. We are focused on the therapeutic areas of metabolic disorders, gastrointestinal disorders and cancer supportive care. We are developing products for the treatment and management of obesity and related conditions, such as type 2 diabetes, of gastrointestinal disorders involving inflammation, such as ulcerative colitis, and of the gastrointestinal side effects of cancer therapy, such as mucositis.
We have a strong and diversified pipeline of commercially significant and distinct product opportunities with attractive risk profiles and potential investment returns and are well placed to achieve our aim of becoming a leading profitable speciality biopharmaceutical development company.